Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.
Front Immunol
October 2024
Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.
Article Synopsis
- - A patient experienced movement and neurocognitive toxicity after receiving ciltacabtagene autoleucel, which did not improve with standard immunosuppression treatments.
- - The patient's symptoms responded positively to a combination of dopaminergic therapies, including carbidopa/levodopa, ropinirole, and amantadine.
- - This case marks the first documented instance of effective symptomatic treatment for a well-known neurotoxic syndrome associated with this therapy.
Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
Lancet Neurol
May 2024
University of Toulouse 3, University Hospital of Toulouse, INSERM, Clinical Investigation Center CIC1436, Department of Neurosciences and Department of Clinical Pharmacology, Toulouse, France; NS-Park/FCRIN Network, Toulouse, France. Electronic address:
Background: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. Levodopa infusion strategies might provide more consistent drug delivery and fewer motor fluctuations. We aimed to assess the safety and efficacy of a continuous 24 h/day subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) compared with oral immediate-release levodopa-carbidopa for the treatment of motor fluctuations in people with Parkinson's disease.
View Article and Find Full Text PDFAn Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects.
Molecules
January 2024
School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23220, USA.
Cannabidiol (CBD), a non-psychoactive compound derived from Cannabis Sativa, has garnered increasing attention for its diverse therapeutic potential. This comprehensive review delves into the complex pharmacokinetics of CBD, including factors such as bioavailability, distribution, safety profile, and dosage recommendations, which contribute to the compound's pharmacological profile. CBD's role as a pharmacological inhibitor is explored, encompassing interactions with the endocannabinoid system and ion channels.
View Article and Find Full Text PDF[A 70-year-old male exhibiting parkinsonism-hyperpyrexia syndrome during levodopa carbidopa intestinal gel (LCIG) treatment and suspected carbidopa allergy due to positive drug-induced lymphocyte stimulation test (DLST)].
Rinsho Shinkeigaku
January 2024
Department of Neurology, National Hospital Organization, Sagamihara National Hospital.
A 70-year-old male who has medical history of Parkinson's disease for 26 years admitted to our hospital for trial of levodopa carbidopa intestinal gel (LCIG) therapy because of severe dyskinesia and frequent wearing-off. He developed deterioration when he was treated with one of the levodopa (LD) decacrboxylase inhibitor compounds in the past. Five days after LD had changed into equivalent dose of LD/carbidopa (CD), high fever with hyperCKemia appeared.
View Article and Find Full Text PDFLevodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results.
J Parkinsons Dis
October 2023
Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Background: Levodopa-carbidopa intestinal gel (LCIG) improves motor and non-motor symptoms in patients with advanced Parkinson's disease (aPD).
Objective: To present the final 36-month efficacy and safety results from DUOGLOBE (DUOdopa/Duopa in Patients with Advanced Parkinson's Disease - a GLobal OBservational Study Evaluating Long-Term Effectiveness; NCT02611713).
Methods: DUOGLOBE was an international, prospective, long-term, real-world, observational study of patients with aPD initiating LCIG in routine clinical care.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!